Myelofibrosis
Myelofibrosis
The latest news, research, and perspectives in myelofibrosis (MF). A primary subtype of myeloproliferative neoplasms (MPNs), this rare blood cancer scars the bone marrow so that it cannot properly produce blood cells.
Advertisement
Melissa BadamoMyelofibrosis | November 4, 2024
Pacritinib demonstrated superiority to best available therapy for spleen volume reduction, total symptom score, and more.
Melissa BadamoMyelofibrosis | November 13, 2024
Patients with splenomegaly are more likely to be referred for HSCT.
Melissa BadamoMyelofibrosis | November 4, 2024
Selinexor plus ruxolitinib was well tolerated, reduced symptom burden, and led to spleen volume reduction.
Melissa BadamoMyelofibrosis | November 4, 2024
One year of pacritinib treatment stabilized or improved thrombocytopenia and anemia in patients with myelofibrosis.
Cailin ConnerMyelofibrosis | October 8, 2024
The phase III PERSIST-2 study compared symptom results from pacritinib with those of best available therapy and ruxolitinib.
Cailin ConnerMyelofibrosis | October 8, 2024
Patients' genomic profiles and baseline laboratory values have implications for their treatment outcomes with these agents.
Advertisement
Cailin ConnerMyelofibrosis | October 8, 2024
The International Prognostic Scoring System, Dynamic International Prognostic Scoring System, and other models were applied.
Cailin ConnerMyelofibrosis | October 9, 2024
A retrospective study found momelotinib plus pacritinib led to reduced need for red blood cell transfusion in patients.
Andrew MorenoMyelofibrosis | September 30, 2024
A real-world retrospective study evaluated transfusion dependent or nondependent patients at ruxolitinib initiation.
Andrew MorenoMyelofibrosis | September 27, 2024
Management of asymptomatic, clinically stable disease is not necessarily improved by implementing routine hemostasis tests.
Andrew MorenoMyelofibrosis | September 27, 2024
Investigational agent DISC-0974 produced anemia response independent of patient transfusion dependency or JAK inhibitor use.
Andrew MorenoMyelofibrosis | September 26, 2024
A study observed that addition of pelabresib to ruxolitinib led to bone marrow microenvironment improvement.
Prithviraj Bose, MDMyelofibrosis | September 25, 2024
An expert on myelofibrosis comments on promising results from current trials and on the need for useful clinical biomarkers.
Melissa BadamoMyelofibrosis | September 13, 2024
History of thrombotic events, hematocrit ≤0.45 L/L, and JAK2 p.V617F were identified as risk factors for progression.
Melissa BadamoMyelofibrosis | September 13, 2024
LOXL2 upregulation is associated with key inflammatory signaling pathways in primary myelofibrosis.
Melissa BadamoMyelofibrosis | September 13, 2024
Treatment with selinexor reduced hepcidin and pro-inflammatory cytokines in patients with myelofibrosis.
Melissa BadamoMyelofibrosis | September 13, 2024
The rates of baseline comorbidities and constitutional symptoms were higher in patients with anemia versus those without.
Rob DillardMyelofibrosis | September 10, 2024
New or worsening anemia following initiation of ruxolitinib does not appear to diminish clinical benefit.
Rob DillardMyelofibrosis | September 10, 2024
Hemoglobin improvement at week 24 after transfusion is associated with improved HRQOL in myelofibrosis and anemia.
Rob DillardMyelofibrosis | September 10, 2024
Prospective analysis suggest that 4.3% of patients with ET progressed to myelofibrosis over five years of follow up.
Advertisement
Advertisement
Editorial Board